- About
- IgAN
- Events
- Resource Center
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
Archives
Kidney Disease In Asian American & Pacific Islanders
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Kidney Disease In Asian American & Pacific Islanders
Background:
More than 24 million individuals of Asian descent are currently living in the US. The Asian American population has increased significantly over the last decade1. Kidney disease related mortality is higher for individuals of Asian descent compared to white patients2. 17% of Asian American and Pacific Islanders are uninsured, limiting detection of hypertension and diabetes, and possibly contributing to the risk of developing kidney disease3.
Did You Know?
The highest prevalence of IgA Nephropathy is seen in individuals of East Asian descent4. Asian patients have lower rates of living donor kidney transplantation at 2 years after being placed on the wait list compared to white patients5
Why Attend This Webinar?
This webinar panel discussion featuring Dr. Naoka Murakami and Kelly Chen, NP-BC will discuss the prevalence of various common and rare kidney diseases and comorbidities among the Asian American and Pacific Islander population and will include both the provider and patient perspectives.
What You Will Learn
- Prevalence of CKD, comorbidities and mortality as it relates to the Asian American and Pacific Islander population.
- How IgAN affects patients of Asian descent
- Trends in kidney transplantation in the Asian American and Pacific Islander population
References:
- Bureau UC. Asian American and Pacific Islander Heritage month: May 2022. Census.gov. April 25, 2023. Accessed November 29, 2023. https://www.census.gov/newsroom/facts-for-features/2022/asian-american-pacific-islander.html
- Claudel SE, Waikar SS, Schmidt IM, Verma A. Kidney disease–related mortality among Asian Americans. Kidney Medicine. 2023;5(8):100676. doi:10.1016/j.xkme.2023.100676.
- Race/ethnicity – kidney disease risk factors. American Kidney Fund. August 7, 2023. Accessed November 28, 2023. https://www.kidneyfund.org/all-about-kidneys/risk-factors/raceethnicity-kidney-disease-risk-factors
- Suzuki Y, Monteiro RC, Coppo R, Suzuki H. The Phenotypic Difference of IgA Nephropathy and its Race/Gender-dependent Molecular Mechanisms. Kidney360. 2021 May 28;2(8):1339-1348. doi: 10.34067/KID.0002972021. PMID: 35369654; PMCID: PMC8676395.
- Purnell TS, Luo X, Cooper LA, Massie AB, Kucirka LM, Henderson ML, Gordon EJ, Crews DC, Boulware LE, Segev DL. Association of Race and Ethnicity With Live Donor Kidney Transplantation in the United States From 1995 to 2014. JAMA. 2018 Jan 2;319(1):49-61. doi: 10.1001/jama.2017.19152. PMID: 29297077; PMCID: PMC5833543.
Naoka Murakami, MD, PhD
Assistant Professor of Medicine, Transplant NephrologistHarvard Medical School, Brigham & Women’s Hospital*
Naoka Murakami, MD PhD, is an Assistant Professor of Medicine at Harvard Medical School and a transplant nephrologist at Brigham and Women’s Hospital. She received her MD-PhD degree from the University of Tokyo, Japan, and completed her Medicine residency at Toranomon Hospital in Japan, and Mount Sinai Beth Israel in New York, followed by a Nephrology fellowship in the combined program at Brigham and Women’s Hospital and Massachusetts General Hospital. Her primary research interest is allograft tolerance and T cell immunobiology. Her research project has been supported by the NIH and the American Society of Nephrology. Her clinical focus is on the care of kidney transplant recipients with cancer (Transplant Onconephrology), in collaboration with Dana-Farber Cancer Institute.
Kelly Chen, NP-BC
Nurse Practitioner, Asian American Engagement DirectorStanford Health Care, IgA Nephropathy Foundation*Kelly Chen is a patient living with IgA Nephropathy as well as a nephrology nurse practitioner. She first received her education from the University of Pennsylvania’s School of Nursing and Wharton School, studying nursing & healthcare management. From first working as a hospital nurse for a few years then transitioning to healthcare consulting, she leveraged her training in both fields. She then went on to complete her graduate nurse practitioner training also at Penn and served as a frontline worker in a medical ICU during the COVID-19 pandemic in New York City at NYU Langone Health. After the pandemic and with her IgAN diagnosis, she returned to her hometown in the San Francisco Bay Area and decided to pivot to caring for kidney patients like herself, working as an ambulatory nephrology nurse practitioner at Stanford Health Care. For the IgAN Foundation, she currently serves as the Medical & Scientific Advisory Board Member as well as the Asian American Engagement Director.
Alf Carroll, DMSc, PA-C
Nephrology Senior Medical Science LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*
Alf Carroll, DMSc, PA-C is a Senior Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization. He earned his Bachelor of Science in Biology and Master of Science in Physician Assistant Studies from Northeastern University in Boston, Massachusetts. He worked clinically as a Physician Assistant in the Emergency Department at Massachusetts General Hospital and South Shore Hospital in the Boston area. Prior to joining Otsuka, Alf held a position at AstraZeneca Pharmaceuticals on their Market Access team focusing on large health systems in New England, covering the cardiovascular, renal, endocrine, and respiratory therapeutic areas.
Jessica Kanai, PharmD
Nephrology Medical Science LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*
Jessica Kanai PharmD, is a Nephrology Medical Science Liaison at Otsuka. Dr Kanai obtained her PharmD from Duquesne University in Pittsburgh, Pennsylvania. She completed her PGY-1 residency at Memorial Health University Medical Center in Savannah, Georgia where she stayed on and worked in both emergency medicine and internal medicine. She was responsible for a diverse patient population including those with end stage renal disease. Dr Kanai then went on to obtain her Australian pharmacy license and worked with numerous specialty services at the Royal Hobart Hospital such as neurosurgery, cardiology and pulmonology. Upon returning to the states, she became the nephrology pharmacist at WVU Medicine and was also involved in initiating pharmacy rounding services with WVU Medicine’s cardiology specialty. Dr Kanai is currently a licensed pharmacist in Pennsylvania and West Virginia.
*Dr Naoka Murakami and Kelly Chen are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Alf Carroll and Dr Jessica Kanai are employees of OPDC.
Registration
Related Events
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved. - IgAN
